THE IMPACT OF COVID-19 AND SARS-COV-2 VACCINATION ON THE FREQUENCY OF HERPES ZOSTER REACTIVATION

Article Sidebar

PDF (Russian)
Published: 2025-12-05
DOI: https://doi.org/10.66073/researchfocus.v4i11.1865
Keywords:
Herpes zoster, Varicella-Zoster Virus, COVID-19, SARS-CoV-2, вакцинация, постгерпетическая невралгия, клеточный иммунитет, факторы риска

Main Article Content

Shoxinova Anaxita Shoxinovna
1st year clinical resident of the Department of Dermatovenereology and Cosmetology of Samarkand State Medical University. Uzbekistan, Samarkand, Amir Temur street, 18,
Narzikulov Rustam Mardonovich
Samarkand State Medical University. Uzbekistan, Samarkand, Amir Temur street, 18,

Abstract

This study presents a comparative clinical and immunological analysis of the frequency and course of herpes zoster in patients who have had COVID-19 and in those vaccinated against SARS-CoV-2, in order to assess the influence of these factors on the reactivation of the Varicella-Zoster virus. The analysis was carried out by comparing three groups of patients. On the basis of clinical data and laboratory indicators, the risk of reactivation, the features of the course of the disease and immunological changes were determined. The incidence, the severity of clinical manifestations and the level of specific immune cells were analysed using statistical methods. In addition, key risk factors were identified, which is an important indicator for clinical prognosis and prevention.

Article Details

Issue

Vol. 4 No. 11 (2025): Research Focus International Scientific Journal. Volume 4, Issue 11 (2025)

Section

14.00.00 – Medical sciences
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

THE IMPACT OF COVID-19 AND SARS-COV-2 VACCINATION ON THE FREQUENCY OF HERPES ZOSTER REACTIVATION. (2025). Research Focus International Scientific Journal, 4(11), 262-271. https://doi.org/10.66073/researchfocus.v4i11.1865

References

Gershon A.A., Breuer J., Cohen J.I., et al. Varicella-zoster virus infection. Nat Rev Dis Primers. 2015;1:15016.

Dworkin R.H., Johnson R.W., Breuer J., et al. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007;44(Suppl 1):S1–26.

Levin M.J. Immune senescence and its role in herpes zoster. J Infect Dis. 2018;218(Suppl 2):S113–S119.

Gilden D., Nagel M.A., Cohrs R.J., et al. The varicella-zoster virus vasculopathies: clinical, CSF, imaging, and virologic features. Neurology. 2013;80:853–860.

Thomas S.L., Hall A.J. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis. 2004;4:26–33.

Chen G., Wu D., Guo W., et al. Clinical and immunologic features in severe and moderate forms of COVID-19. J Clin Invest. 2020;130(5):2620–2629.

Zheng M., Gao Y., Wang G., et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17:533–535.

Blanco-Melo D., Nilsson-Payant B.E., Liu W.-C., et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181:1036–1045.

Saade A., Moratelli G., Azoury R., et al. Herpes zoster following COVID-19 infection: a systematic review. Dermatol Ther. 2021;34:e15036.

Tammaro A., Adebanjo G.A., Parisella F.R., et al. Cutaneous manifestations in COVID-19: epidemiology and clinical features. J Eur Acad Dermatol Venereol. 2021;35:e299–e303.

Maalej M., Slouma M., Ben Dhaou B., et al. Herpes zoster after SARS-CoV-2 infection: a multicenter retrospective study. Infect Dis Now. 2022;52:103–107.

Elsaie M.L., Youssef E.G., Nada H.A. Herpes zoster may be a marker for underlying COVID-19 infection. Infect Drug Resist. 2020;13:2179–2182.

Wollina U., Karadağ A.S., Rowland-Payne C., et al. Herpes zoster and COVID-19: review of the literature. Dermatol Ther. 2021;34:e14982.

Rodríguez-Jiménez P., Chicharro P., Cabrera L.M., et al. Varicella-zoster virus reactivation after SARS-CoV-2 infection. Int J Dermatol. 2021;60:882–884.

Park A., Iwasaki A. Type I and type III interferons — induction, signaling, evasion, and application to combat COVID-19. Cell Host Microbe. 2020;27:870–878.

Choudhury A., Mukherjee S. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs. J Med Virol. 2020;92:2105–2113.

Furer V., Eviatar T., Zisman D., et al. Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series. Rheumatology. 2021;60(SI):SI90–SI95.

Psichogiou M., Samarkos M., Mikos N., Hatzakis A. Reactivation of varicella zoster virus after vaccination against SARS-CoV-2: a systematic review. J Eur Acad Dermatol Venereol. 2022;36:1342–1354.

Lee C., Cotter D., Basa J., Greenberg H.L. Varicella-zoster virus reactivation after mRNA-1273 (Moderna) COVID-19 vaccination. Cureus. 2021;13:e14272.

Chua J.V., Chen J.J. Herpes zoster reactivation after CoronaVac vaccination. J Eur Acad Dermatol Venereol. 2021;35:e620–e622.

Arvin A.M. Cell-mediated immunity to varicella-zoster virus. J Infect Dis. 1992;166(Suppl 1):S35–S41.

Zhou R., To K.K.-W., Wong Y.-C., et al. Acute SARS-CoV-2 infection impairs dendritic cell and T cell function. Immunity. 2020;53:864–877.

Netea M.G., Domínguez-Andréa J., Barreiro L.B., et al. Defining trained immunity and its role in health and disease. Nat Rev Immunol. 2020;20:375–388.

Barda N., Dagan N., Ben-Shlomo Y., et al. Safety of the BNT162b2 mRNA COVID-19 vaccine in a nationwide setting. N Engl J Med. 2021;385:1078–1090.

Desai H.D., Sharma K., Nayan N., et al. A systematic review on herpes zoster following COVID-19 vaccination. Int J Infect Dis. 2022;114:58–63.

Debisarun P.A., Gössling K.L., Bulut O., et al. Induction of trained immunity by influenza vaccination — impact on COVID-19. Nat Microbiol. 2021;6:1098–1111.